Welcome to Team Genus
Asset Allocation & Portfolio Management Tools for Investors
 
  • Welcome : Guest
  • Icon
 
About Team Genus Post your feedback Client Registration
Your Current Location : Fund Card : Portfolio Classification
 
Nippon India Nifty Pharma ETF
[Equity: Index]
 
Asset Mix
 
Instruments Breakdown
Instruments Composition
Current Asset -0.01
Equity 99.78
Trep 0.23
 
Concentration Analysis
Top 5 Holdings 63.01%
Top 10 Holdings 81.59%
Top 25 Holdings 100.00%
 
Sector Analysis
Sector/Ratings Net Asset(%)
Pharma & Biotech 99.78
Cash 0.22
 
Portfolio Metrics
PB Ratio 4.83
PE Ratio 35.22
 
Top 25 Holdings
Holdings Net Asset(%)
Sun Pharmaceutical Industries Limited 26.80
Cipla Limited 12.03
Dr Reddys Laboratories Limited 11.48
DIVI LABORATORIES LTD 6.72
Lupin Limited 5.98
Aurobindo Pharma Limited 4.69
Zydus Lifesciences Limited 3.90
Alkem Laboratories Limited 3.80
Torrent Pharmaceuticals Limited 3.64
IPCA Laboratories Limited 2.55
MANKIND PHARMA LIMITED 2.54
Laurus Labs Limited 2.36
Abbott India Limited 2.21
Glenmark Pharmaceuticals Limited 2.20
Gland Pharma Limited 1.95
Biocon Limited 1.80
J B Chemicals and Pharma Limited 1.80
Natco Pharma Limited 1.32
Sanofi India Limited 1.12
Granules India Limited 0.89
Triparty Repo 0.23
Net Current Assets -0.01
 
 
Sector Analysis Graphical Mode
 
 
 
useful links Reserve Bank of India
 
FUNDS : 360  |  Aditya  |  Axis  |  Bajaj  |  Bandhan  |  Bank  |  Baroda  |  Canara  |  DSP  |  Edelweiss  |  Edelweiss  |  Franklin  |  Groww  |  HDFC  |  Helios  |  HSBC  |  ICICI  |  Invesco  |  ITI  |  JM  |  Kotak  |  LIC  |  Mahindra  |  Mirae  |  Motilal  |  NAVI  |  Nippon  |  NJ  |  Old  |  PGIM  |  PPFAS  |  Quant  |  Quantum  |  Samco  |  SBI  |  Shriram  |  Sundaram  |  Tata  |  Taurus  |  TRUST  |  Union  |  UTI  |  WhiteOak  |  Zerodha  | 
 

Disclaimer: While all efforts have been taken to make this web site as authentic as possible, Team Genus Financial Services Private Limited (www.teamgenus.in) will not be responsible for any loss to any person/entity caused by any short-coming; defect or inaccuracy inadvertently or otherwise crept in the teamgenus.in web site. Mutual Fund Investments are subject to market risks, read all scheme related documents carefully before investing into Mutual Funds. The use of information and services is subject to the terms and conditions governing this website.

Follow Us on
Design & Developed by : InvestWell